We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Patricia Cappuyns
Cappuyns Intellectual Property Law
As a result of the pharma sector inquiry opened in January 2008, the European Commission issued three decisions for “pay-for-delay” competition law violations in the pharmaceutical industry: the Lundbeck decision re Citalopram in June 2013, the Fentanyl decision in December 2013 and the Servier decision re Perindopril in July 2014. An investigation of Cephalon and Teva concerning Modafinil is still pending.
